B-cell depletion and clinical improvement were recently reported using the CD19 × CD3 bispecific blinatumomab (administered as a continuous infusion for 5 days per cycle) to treat 6 patients with RA (2 cycles) (63) and a patient with rapidly progressive severe systemic sclerosis (4 cycles) (64). Here, CD19 is linked to systemic sclerosis.